首页> 外文期刊>Circulation journal >Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.
【24h】

Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.

机译:阿托伐他汀治疗对高胆固醇血症患者在2周内对低密度脂蛋白亚组分,残留样颗粒胆固醇和氧化型低密度脂蛋白的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The short- and intermediate-term pleiotropic effects of atorvastatin were investigated in 18 hypercholesterolemic patients, as well as the temporal differences in these pleiotropic effects. Atorvastatin was given for 3 months and fasting lipid concentrations, thiobarbituric acid reactive substances (TBARS), fibrinolytic parameters, and flow-mediated dilation of the brachial artery (FMD) were measured at baseline and after 2 weeks and 3 months of therapy. Atorvastatin reduced the total cholesterol (273+/-34 vs 188+/-31 mg/dl, p<0.0001), low-density lipoprotein-cholesterol (LDL-C: 174+/-28 vs 111+/-23 mg/dl, p<0.0001), small, dense LDL-C (34+/-22 vs 18+/-20%, p<0.01), remnant-like particles cholesterol (RLP-C: 8.8+/-6.0 vs 5.1+/-2.6 mg/ml, p<0.01), and TBARS (3.3+/-1.0 vs 3.1+/-0.9 nmol/ml, p<0.05) after 2 weeks. Atorvastatin decreased the concentration of small, dense LDL-C again after 3 months (8+/-13%, p<0.0001). The plasma concentrations of the fibrinolytic parameters did not change significantly after 3 months of atorvastatin therapy. FMD increased significantly after 2 weeks (5.6+/-2.1 vs 6.3+/-2.0%, p<0.01) and additionally increased after 3 months of therapy (8.3+/-1.9%, p<0.0001). There were no correlations between the pleiotropic effects and the improvement in the lipid profile. The results indicate some short-term pleiotropic effects of atorvastatin therapy within 2 weeks, which may be important with respect to the early benefits of statin therapy.
机译:在18名高胆固醇血症患者中研究了阿托伐他汀的短期和中期多效作用,以及这些多效作用的时间差异。给予阿托伐他汀3个月,在基线时以及治疗2周和3个月后测量空腹血脂浓度,硫代巴比妥酸反应性物质(TBARS),血纤蛋白溶解参数和肱动脉血流介导的扩张(FMD)。阿托伐他汀降低了总胆固醇(273 +/- 34 vs 188 +/- 31 mg / dl,p <0.0001),低密度脂蛋白胆固醇(LDL-C:174 +/- 28 vs 111 +/- 23 mg / dl,p <0.0001),小而致密的LDL-C(34 +/- 22 vs 18 +/- 20%,p <0.01),残留物样胆固醇(RLP-C:8.8 +/- 6.0 vs 5.1+ 2周后,检测到-2.6 mg / ml,p <0.01)和TBARS(3.3 +/- 1.0与3.1 +/- 0.9 nmol / ml,p <0.05)。阿托伐他汀在3个月后再次降低了小而密集的LDL-C的浓度(8 +/- 13%,p <0.0001)。阿托伐他汀治疗3个月后,血浆纤溶蛋白浓度没有明显变化。 FMD在2周后显着增加(5.6 +/- 2.1对6.3 +/- 2.0%,p <0.01),在治疗3个月后进一步增加(8.3 +/- 1.9%,p <0.0001)。多效作用与脂质分布的改善之间没有相关性。结果表明,阿托伐他汀治疗在2周内有一些短期多效作用,这对于他汀类药物治疗的早期获益可能是重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号